Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier
Abstract Introduction Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early‐stage subjects do not worsen clinically during a clinical trial, and a neurodegenerative measure predictive of decline...
Saved in:
| Main Authors: | Dawn C. Matthews, Ana S. Lukic, Randolph D. Andrews, Miles N. Wernick, Stephen C. Strother, Mark E. Schmidt, for the Alzheimer's Disease Neuroimaging Initiative |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12325 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Watchful waiting in laryngo‐tracheobronchial amyloid: A case report
by: Dylan Beinart, et al.
Published: (2024-11-01) -
Neutrophils enhance the clearance of systemic amyloid deposits in a murine amyloidoma model
by: Trevor J. Hancock, et al.
Published: (2024-11-01) -
The role of neuroinflammation in cerebral amyloid angiopathy
by: Hilde van den Brink, et al.
Published: (2024-12-01) -
Serum amyloid A1 (SAA1) protein in human colostrum
by: George H. Sack Jr, et al.
Published: (2018-03-01) -
Enhancing Amyloid PET Quantification: MRI-Guided Super-Resolution Using Latent Diffusion Models
by: Jay Shah, et al.
Published: (2024-12-01)